---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039997"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:23:44.580755+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience reports Q3 2023 cash of $13.8M; XACIATO milestone triggered

## Summary
- Cash and equivalents $13.8M at September 30, 2023; evaluating financing options.
- R&D expenses increased to $6.7M in Q3 2023 from $4.5M in Q3 2022, driven by Sildenafil Cream and Ovaprene activities.
- G&A expenses unchanged at $2.7M; focus on efficient operations.
- Received $1.8M first commercial milestone payment from Organon for XACIATO US launch.
- On track to start Ovaprene Phase 3 enrollment in Q4 2023 and end-of-Phase 2 meeting for Sildenafil Cream with FDA.

## SEC filing metadata
- accession: 0001493152-23-039997
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315223039997/0001493152-23-039997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315223039997/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039997
- JSON: https://secwatch.observer/filing/0001493152-23-039997.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039997.txt

## Key facts
- Earnings Releases
  Dare Bioscience, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315223039997/0001493152-23-039997-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.